{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:18:38Z","timestamp":1767964718987,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:00:00Z","timestamp":1634169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:00:00Z","timestamp":1634169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP18K09297"],"award-info":[{"award-number":["JP18K09297"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s10147-021-02050-3","type":"journal-article","created":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T13:38:39Z","timestamp":1634218719000},"page":"441-447","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prospective feasibility study of neoadjuvant dose-dense paclitaxel plus carboplatin with bevacizumab therapy followed by interval debulking surgery for advanced ovarian, fallopian tube, and primary peritoneal cancer patients"],"prefix":"10.1007","volume":"27","author":[{"given":"Naomi","family":"Iwasa-Inoue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8996-4284","authenticated-orcid":false,"given":"Hiroyuki","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumio","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuyuki","family":"Chiyoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Yoshihama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiko","family":"Nanki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Yamagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Morisada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Hirasawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,14]]},"reference":[{"key":"2050_CR1","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"A du Bois","year":"2009","unstructured":"du Bois A, Reuss A, Pujade-Lauraine E et al (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux Pour les Etudes des Cancers de l\u2019Ovaire (GINECO). Cancer 115:1234\u20131244","journal-title":"Cancer"},{"key":"2050_CR2","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.ygyno.2006.06.025","volume":"103","author":"RE Bristow","year":"2006","unstructured":"Bristow RE, Chi DS (2006) Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 103:1070\u20131076","journal-title":"Gynecol Oncol"},{"key":"2050_CR3","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1245\/s10434-009-0558-6","volume":"16","author":"S Kang","year":"2009","unstructured":"Kang S, Nam BH (2009) Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies. Ann Surg Oncol 16:2315\u20132320","journal-title":"Ann Surg Oncol"},{"key":"2050_CR4","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote I, Trop\u00e9 CG, Amant F et al (2010) European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943\u2013953","journal-title":"N Engl J Med"},{"key":"2050_CR5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","volume":"386","author":"S Kehoe","year":"2015","unstructured":"Kehoe S, Hook J, Nankivell M et al (2015) Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 386:249\u2013257","journal-title":"Lancet"},{"key":"2050_CR6","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/S1470-2045(18)30566-7","volume":"19","author":"I Vergote","year":"2018","unstructured":"Vergote I, Coens C, Nankivell M et al (2018) EORTC; MRC CHORUS study investigators. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol 19:1680\u20131687","journal-title":"Lancet Oncol"},{"key":"2050_CR7","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","volume":"374","author":"N Katsumata","year":"2009","unstructured":"Katsumata N, Yasuda M, Takahashi F et al (2009) Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374:1331\u20131338","journal-title":"Lancet"},{"key":"2050_CR8","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA et al (2011) Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473\u20132483","journal-title":"N Engl J Med"},{"key":"2050_CR9","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J et al (2011) ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484\u20132496","journal-title":"N Engl J Med"},{"key":"2050_CR10","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.1016\/j.ejca.2013.08.002","volume":"49","author":"A Gonzalez-Martin","year":"2013","unstructured":"Gonzalez-Martin A, Gladieff L, Tholander B et al (2013) OCTAVIA Investigators. Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer. Eur J Cancer 49:3831\u20133838","journal-title":"Eur J Cancer"},{"key":"2050_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejca.2016.05.017","volume":"264","author":"T Onda","year":"2016","unstructured":"Onda T, Satoh T, Saito T et al (2016) Japan Clinical Oncology Group. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III\/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. Eur J Cancer 264:22\u201331","journal-title":"Eur J Cancer"},{"key":"2050_CR12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejca.2020.02.020","volume":"130","author":"T Onda","year":"2020","unstructured":"Onda T, Satoh T, Ogawa G et al (2020) Japan Clinical Oncology Group. Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III\/IV ovarian, tubal and peritoneal cancers in phase III randomised trial. Eur J Cancer 130:114\u2013125","journal-title":"Eur J Cancer"},{"key":"2050_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejca.2016.01.017","volume":"59","author":"A Fagotti","year":"2016","unstructured":"Fagotti A, Ferrandina G, Vizzielli G et al (2016) Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome. Eur J Cancer 59:22\u201333","journal-title":"Eur J Cancer"},{"key":"2050_CR14","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/jjco\/hyx118","volume":"47","author":"T Yoshihama","year":"2017","unstructured":"Yoshihama T, Nomura H, Iwasa N et al (2017) Efficacy and safety of dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube or peritoneal cancer. Jpn J Clin Oncol 47:1019\u20131023","journal-title":"Jpn J Clin Oncol"},{"key":"2050_CR15","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s00280-016-3187-3","volume":"78","author":"T Ebata","year":"2016","unstructured":"Ebata T, Yunokawa M, Bun S et al (2016) Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas. Cancer Chemother Pharmacol 78:1283\u20131288","journal-title":"Cancer Chemother Pharmacol"},{"key":"2050_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejca.2016.09.036","volume":"70","author":"R Rouzier","year":"2017","unstructured":"Rouzier R, Gouy S, Selle F et al (2017) Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: results from the ANTHALYA trial. Eur J Cancer 70:133\u2013142","journal-title":"Eur J Cancer"},{"key":"2050_CR17","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1245\/s10434-015-4651-8","volume":"22","author":"M Petrillo","year":"2015","unstructured":"Petrillo M, Paris I, Vizzielli G et al (2015) Neoadjuvant chemotherapy followed by maintenance therapy with or without bevacizumab in unresectable high-grade serous ovarian cancer: a case-control study. Ann Surg Oncol 22:952\u2013958","journal-title":"Ann Surg Oncol"},{"key":"2050_CR18","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/jso.25187","volume":"118","author":"S Komiyama","year":"2018","unstructured":"Komiyama S, Kugimiya T, Kubushiro K (2018) Safety and efficacy of neoadjuvant chemotherapy containing bevacizumab and interval debulking surgery for advanced epithelial ovarian cancer: a feasibility study. J Surg Oncol 118:687\u2013693","journal-title":"J Surg Oncol"},{"key":"2050_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ygyno.2015.07.103","volume":"139","author":"JS Ferriss","year":"2015","unstructured":"Ferriss JS, Java JJ, Bookman MA et al (2015) Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology\/GOG study. Gynecol Oncol 139:17\u201322","journal-title":"Gynecol Oncol"},{"key":"2050_CR20","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.ygyno.2016.12.011","volume":"144","author":"G Daniele","year":"2017","unstructured":"Daniele G, Lorusso D, Scambia G et al (2017) Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): a subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial. Gynecol Oncol 144:256\u2013259","journal-title":"Gynecol Oncol"},{"key":"2050_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10147-018-1319-y","volume":"24","author":"S Komiyama","year":"2019","unstructured":"Komiyama S, Kato K, Inokuchi Y et al (2019) Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial). Int J Clin Oncol 24:103\u2013114","journal-title":"Int J Clin Oncol"},{"key":"2050_CR22","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G et al (2018) Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379:2495\u20132505","journal-title":"N Engl J Med"},{"key":"2050_CR23","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I et al (2019) PRIMA\/ENGOT-OV26\/GOG-3012 investigators. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 381:2391\u20132402","journal-title":"N Engl J Med"},{"key":"2050_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ygyno.2008.12.027","volume":"113","author":"T Onda","year":"2009","unstructured":"Onda T, Kobayashi H, Nakanishi T et al (2009) Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III\/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206. Gynecol Oncol 113:57\u201362","journal-title":"Gynecol Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-021-02050-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-021-02050-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-021-02050-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T16:25:04Z","timestamp":1643991904000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-021-02050-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,14]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["2050"],"URL":"https:\/\/doi.org\/10.1007\/s10147-021-02050-3","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,14]]},"assertion":[{"value":"22 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hiroyuki Nomura reports grants from Japan Society for the Promotion of Science, during the conduct of the study. All other authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}